breast cancer, AstraZeneca and US FDA

US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Drug in clinical trials for breast cancer could also treat some blood cancers
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
Improving Treatment Access to Innovative Therapies in Breast Cancer
Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.
FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer.
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
The Power of Personalized Breast Cancer Care
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
AdventHealth in Palm Coast adds advanced cancer treatment center to its Flagler campus
The $30 million facility was made possible, in part, through a $4 million contribution through the AdventHealth Palm Coast ...
Danielle Fishel ‘officially done’ with cancer treatment after 20 rounds of radiation: ‘Hurts to be awake’
Danielle Fishel has completed her breast cancer treatment. The “Boy Meets World” alum, 43, revealed she’s “officially” done ...
Q&A: Morgan Pressel on $1M raised to fight breast cancer, plus Nelly, Lexi, Lydia in 2025
Morgan Pressel's 18th annual Morgan & Friends event raised a record $1,022,000 to support the fight against breast cancer.
Medscape21h
Breast Cancer Screening at 40 Seems Cost-Effective in Canada
As cancer treatment costs have increased, identifying and treating early-stage cancer sooner reduces expenses and improves ...
Women on Medicaid at Higher Risk of Breast Cancer
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.